Nelfinavir Boosts Bioavailability of Saquinavir in HIV- Positive Patients

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Nelfinavir Boosts Bioavailability of Saquinavir in HIV- Positive Patients

Reuters Health Information Services (12/12/97)

Abstract: A group of U.K. and Irish researchers, led by David Black of the University of Liverpool, recently found that the use of two protease inhibitors with two nucleoside analogues helps boost protease inhibitor bioavailability to the therapeutic range among some patients. According to the study, published in the December issue of AIDS, the use of nelfinavir raises the bioavailability of saquinavir by five times. In the study, that was conducted with six HIV-positive patients, Black and his colleagues first provided a three-drug combination therapy, and then added nelfinavir three times daily for two days. The team concluded that for some patients, the use of nelfinavir boosted the efficacy of the drug levels to the therapeutic range. However, the variability among patients' baseline plasma saquinavir levels indicates that most effective dosing should be individualized.

971215
AD972289

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.